4SC Archives

Best in Biotech 4 Nov 2019

Top 10 Biotech Companies Leaving a Mark in Munich

These are the top 10 biotech companies in Munich, one of the hottest hubs for the biotechnology industry. One of the largest cities in Germany, Munich is a hub for science and technology. Biotechnology is one of its many strengths, supported by strong academic research at the city’s two top universities: Ludwig Maximilian University and […]

November 4, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Oct 2019

RNA Therapies, Immunotherapies and Cancer Tests Showcased in Spain

Biotech companies around the world gathered in Barcelona, Spain, to present breakthroughs in cancer diagnostics and treatments such as cell therapies and cancer vaccines. Here’s our take on the most interesting offerings from the European crop. Barcelona is the home of Gaudi and Barcelona Football Club. Over the last few days, it was also the […]

October 2, 2019 - 6 minutesmins - By Jonathan Smith

News and Trends 13 Sep 2017

Epigenetics Drug Proves Effective in Phase I for Lethal Cancer

4SC’s partner Yakult Honsha has presented positive results at ESMO 2017 for the epigenetics drug resminostat in a Phase I trial run in Japan. The histone deacetylase (HDAC) inhibitor resminostat has shown to induce tumor shrinkage or disease stabilization in all patients with biliary tract cancer in a Phase I trial. The goal was to determine […]

September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

epigenetics review cambridge epigenetix oryzon1

In Depth 5 Sep 2017

The Next Generation of Genetic Medicine: A Review of Epigenetics

The field of genetics has long been an object of global fascination, beginning with Mendel’s pea plant experiments in the 19th century and peaking when the human genome was sequenced (albeit not completely) in 2003. But epigenetics as the next level up from genetics is still mysterious to most. Efforts are already underway to make […]

September 5, 2017 - 9 minutesmins - By Evelyn Warner

News and Trends 18 Jul 2017

German Biotech Strikes License Deal with Japanese Dermatology Firm

4SC has granted an exclusive worldwide license to the Japanese dermatology firm Maruho on a class of compounds against the Kv1.3 ion channel. Under the agreement, 4SC could receive up to €105M in upfront and milestone payments plus royalties on future sales. The deal is part of the German company’s strategy to out license non-core […]

July 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 8 Jun 2016

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

Pharma and Biotech from every corner flocked to Chicago for the beginning of June. Why? It’s where one of the biggest oncology events happens – the ASCO Annual Meeting 2016. Shortly after the AACR annual meeting (with presentations from several European Biotechs), it’s time for the ASCO annual meeting. Hosted by the American Society of Clinical […]

June 8, 2016 - 7 minutesmins - By Denise Neves Gameiro

News and Trends 24 Feb 2016

German Biotech wins FDA Approval for New Liver Cancer Trial

4SC, in Germany, has the FDA’s green light to conduct efficacy trials in the US with a candidate drug against hepatocellular carcinoma. Munich-based 4SC’s lead candidate, resminostat, is a small-molecule being tested in several trials for some of the deadliest cancers. These include liver – which is also known as hepatocellular carcinoma (HCC). Resminostat is an inhibitor of histone […]

February 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 23 Nov 2014

Munich: Why is it One of the Best Biotech Cluster in Europe ?

The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue and staff numbers despite ever-increasing international competition. This continues Munich’s status as one of the pre-eminent locations for this future-oriented industry. This was confirmed by the latest study carried out by the City of Munich, the IHK and BioM based […]

November 23, 2014 - 3 minutesmins - By Julie Lellouche

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us